Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy

Frontiers in Immunology(2021)10.3389/fimmu.2020.561083Source: DataRank Database

Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy is a research paper published in Frontiers in Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 18 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access18 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.22)OA: goldTopics (51)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Ruifeng Guo ORCID,Sean S. Park ORCID,Joerg Herrmann ORCID,Haidong Dong ORCID,Yiyi Yan ORCID

Live enrichment

PubMed:33603731 PMC:PMC7884751 OpenAlex:https://openalex.org/W3128625275

National Institutes of Health

Grant: K12CA090628, R01 CA 200551, P30 CA 15083

NCI NIH HHS

Grant: R01 CA200551

NCI NIH HHS

Grant: K12 CA090628

Richard M. Schulze Family Foundation

FWCI

1.22

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.561083/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.561083/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.561083/full

journalhttps://doi.org/10.3389/fimmu.2020.561083

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33603731

Fields of Study

Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchMelanoma and MAPK PathwaysAgedBiomarkersBiomarkers, TumorBiopsyDisease ManagementDisease ProgressionDisease SusceptibilityFemaleHumansImmune Checkpoint InhibitorsMelanomaMultimodal ImagingMyocarditisT-Lymphocyte Subsets

MeSH Terms

Immune Checkpoint InhibitorsAgedBiopsyDisease SusceptibilityFemaleHumansMelanomaMyocarditisBiomarkers, TumorBiomarkersT-Lymphocyte SubsetsDisease ProgressionDisease ManagementMultimodal Imaging

Keywords

NivolumabFulminantMedicineIpilimumabMyocarditisMelanomaImmune checkpointTumor-infiltrating lymphocytesCD8GranzymeImmune systemImmunologyCancer researchImmunotherapyInternal medicinePerforinCase ReportImmune Checkpoint InhibitorsCytolytic T LymphocytesHyperprogression

Sustainable Development Goals

SDG 0: Good health and well-being